Hepatitis delta in patients with resolved hepatitis B virus infection

dc.creatorAguilera, Antonio
dc.creatorRodríguez-Calviño, Javier
dc.creatorMendoza, Carmen de
dc.creatorSoriano, Vicente (1)
dc.date.accessioned2019-01-22T12:09:36Z
dc.date.accessioned2023-03-07T19:19:56Z
dc.date.available2019-01-22T12:09:36Z
dc.date.available2023-03-07T19:19:56Z
dc.date.created2019-01-22T12:09:36Z
dc.identifier1473-5687
dc.identifierhttps://reunir.unir.net/handle/123456789/7677
dc.identifierhttps://doi.org/10.1097/MEG.0000000000001187
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5902271
dc.description.abstractBackground The hepatitis delta virus (HDV) causes the most aggressive form of chronic viral hepatitis. As HDV replication requires hepatitis B virus (HBV), HDV screening is limited to HBsAg+ carriers. To date, individuals with HDV-antibodies and markers of resolved hepatitis B are considered cured. However, a subset shows elevated liver enzymes and hepatic fibrosis. Could they represent HBsAg-seronegative occult HDV infections? Methods We tested for HDV-antibodies 406 individuals with markers of past HBV exposure. Results Overall, 20 (4.9%) were reactive for HDV-antibodies. All were negative for serum HDV-RNA, including four with elevated liver enzymes. Conclusion These results support the current policy of screening for hepatitis delta only in HBsAg+ individuals.
dc.languageeng
dc.publisherEuropean Journal of Gastroenterology & Hepatology
dc.relation;vol. 30, nº 9
dc.rightsclosedAccess
dc.subjecthepatitis B
dc.subjecthepatitis C
dc.subjecthepatitis delta
dc.subjectHIV
dc.subjectoccult hepatitis
dc.subjectJCR
dc.subjectScopus
dc.titleHepatitis delta in patients with resolved hepatitis B virus infection
dc.typeArticulo Revista Indexada


Este ítem pertenece a la siguiente institución